The Potential Effect of Statins on Rituximab Immunotherapy

1. MaloneyDGGrillo-LopezAJWhiteCABodkinDSchilderRJ

1997

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Blood

90

2188

2195

2. EdwardsJCSzczepanskiLSzechinskiJFilipowicz-SosnowskaAEmeryP

2004

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

N Engl J Med

350

2572

2581

3. EdwardsJCCambridgeG

2006

B-cell targeting in rheumatoid arthritis and other autoimmune diseases.

Nat Rev Immunol

6

394

403

4. CoiffierBLepageEBriereJHerbrechtRTillyH

2002

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

N Engl J Med

346

235

242

5. HiddemannWBuskeCDreylingMWeigertOLenzG

2005

Treatment strategies in follicular lymphomas: current status and future perspectives.

J Clin Oncol

23

6394

6399

6. MarcusRImrieKBelchACunninghamDFloresE

2005

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Blood

105

1417

1423

7. MaloneyDGSmithBRoseA

2002

Rituximab: mechanism of action and resistance.

Semin Oncol

29

2

9

8. MaloneyDG

2003

Rituximab for follicular lymphoma.

Curr Hematol Rep

2

13

22

9. EndoA

1992

The discovery and development of HMG-CoA reductase inhibitors.

J Lipid Res

33

1569

1582

10. XiaZTanMMWongWWDimitroulakosJMindenMD

2001

Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.

Leukemia

15

1398

1407

11. KatanoHPesnicakLCohenJI

2004

Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas.

Proc Natl Acad Sci U S A

101

4960

4965

12. ZhuangLKimJAdamRMSolomonKRFreemanMR

2005

Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts.

J Clin Invest

115

959

968

13. WongWWClendeningJWMartirosyanABoutrosPCBrosC

2007

Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma.

Mol Cancer Ther

6

1886

1897

14. PhamLVTamayoATYoshimuraLCLoPTerryN

2002

A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas.

Immunity

16

37

50

15. TauzinSDingHKhatibKAhmadIBurdevetD

2007

Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts.

Blood

111

2310

2320

16. WiniarskaMBilJWilczekEWilczynskiGMLekkaM

2008

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.

PLoS Med

5

e64

doi:10.1371/journal.pmed.0050064

17. ClynesRATowersTLPrestaLGRavetchJV

2000

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.

Nat Med

6

443

446

18. CraggMSMorganSMChanHTMorganBPFilatovAV

2003

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.

Blood

101

1045

1052

19. Di GaetanoNCitteraENotaRVecchiAGriecoV

2003

Complement activation determines the therapeutic activity of rituximab in vivo.

J Immunol

171

1581

1587

20. CartronGDacheuxLSallesGSolal-CelignyPBardosP

2002

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Blood

99

754

758

21. ShanDLedbetterJAPressOW

1998

Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.

Blood

91

1644

1652

22. ByrdJCKitadaSFlinnIWAronJLPearsonM

2002

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.

Blood

99

1038

1043

23. GlennieMFrenchRCraggMTaylorR

2007

Mechanisms of killing by anti-CD20 monoclonal antibodies.

Mol Immunol

44

3823

3837

24. PolyakMJAyerLMSzczepekAJDeansJP

2003

A cholesterol-dependent CD20 epitope detected by the FMC7 antibody.

Leukemia

17

1384

1389

25. CraggMSWalsheCAIvanovAOGlennieMJ

2005

The biology of CD20 and its potential as a target for mAb therapy.

Curr Dir Autoimmun

8

140

174

26. GallonLChhabraD

2006

Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient.

Am J Transplant

6

3017

3021

27. WongWWDimitroulakosJMindenMDPennLZ

2002

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis.

Leukemia

16

508

519

28. van de DonkNWSchotteDKamphuisMMvan MarionAMvan KesselB

2003

Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells.

Clin Cancer Res

9

5735

5748